Skip to Content
Merck

Comprehensive Profiling of HIV Antibody Evolution.

Cell reports (2019-05-03)
Susan H Eshleman, Oliver Laeyendecker, Kai Kammers, Athena Chen, Mariya V Sivay, Sanjay Kottapalli, Brandon M Sie, Tiezheng Yuan, Daniel R Monaco, Divya Mohan, Daniel Wansley, Tomasz Kula, Charles Morrison, Stephen J Elledge, Ron Brookmeyer, Ingo Ruczinski, H Benjamin Larman
ABSTRACT

This study evaluates HIV antibody responses and their evolution during the course of HIV infection. A phage display system is used to characterize antibody binding to >3,300 HIV peptides in 57 adults with early- to late-stage infection. We find that the number of unique epitopes targeted ("antibody breadth") increases early in infection and then stabilizes or declines. A decline in antibody breadth 9 months to 2 years after infection is associated with subsequent antiretroviral treatment (ART) initiation, and a faster decline in antibody breadth is associated with a shorter time to ART initiation. We identify 266 peptides with increasing antibody reactivity over time and 43 peptides with decreasing reactivity over time. These data are used to design a prototype four-peptide "serosignature" to predict duration of HIV infection. We also demonstrate that epitope engineering can be used to optimize peptide binding properties for applications such as cross-sectional HIV incidence estimation.